MR-guided radiotherapy
HCA Healthcare UK invests £15million to introduce advanced MR-guided radiotherapy with Elekta Unity MR Linac
Professor Peter Schmid
Consultant Oncologist, HCA Healthcare UK
Professor Peter Schmid is an internationally renowned medical oncologist specialising in breast cancer. He is Chair in Cancer Medicine at Barts Cancer Institute, Queen Mary University of London, and Clinical Director of the Breast Cancer Centre at St Bartholomew’s Hospital, alongside his role at HCA Healthcare UK.
Professor Schmid has led multiple landmark international trials that have redefined standards of care, particularly in immunotherapy and triple negative breast cancer. His work focuses on translating cancer biology into more effective, targeted and less toxic systemic therapies.
In his session, Peter will be exploring the evolution of systemic (medical) anti-cancer treatments and how the rapid innovation in this space is leading to improved outcomes and patient experience.
Systemic (medical) treatments
Key takeaways
- Innovation in oncology treatments leads to significant improvements in outcomes.
- The increasing treatment complexity requires optimised, multi-disciplinary working of highly specialised teams to keep up with the rapidly evolving field.
- Robust pathways, governance, delivery and safety systems are critical for optimal patient outcomes.